Inhibitors of pcsk9
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- DRAUPNIR BIO APS
- Filing Date
- 2024-08-23
- Publication Date
- 2026-07-01
AI Technical Summary
Current therapies for lowering LDL cholesterol levels, such as statins, have limitations including side effects and increased expression of PCSK9, which counteracts their beneficial effects. Additionally, there is a need for small molecule compounds that can effectively bind PCSK9, offering improved efficacy and ease of administration compared to biologic therapies.
Development of novel small molecule PCSK9 inhibitors that modulate the activity of PCSK9 and bind to it with high affinity, providing a pharmacologically acceptable salt form for use as medicaments. These compounds are designed to overcome the drawbacks of biologic therapies by offering oral bioavailability, reduced immunogenicity, and lower costs.
The small molecule PCSK9 inhibitors effectively reduce LDL cholesterol levels and mitigate the risk of atherosclerotic cardiovascular disease events without major adverse effects, providing a more convenient and cost-effective treatment option compared to existing biologic therapies.
Smart Images
Figure IMGF000003_0001 
Figure IMGF000005_0001 
Figure IMGF000005_0002